Moderately bullish activity in Pfizer with shares up 0.41%
Moderately bullish activity in Pfizer (PFE), with shares up 10c, or 0.41%, near $25.77. Options volume relatively light with 66k contracts traded and calls leading puts for a put/call ratio…
Fiscal Year: January - December
Pfizer Inc. (PFE), listed on the NYSE, has a market capitalization of $146.99B. As of May 20, 2026, the stock is trading at $25.79 per share@else an unavailable price , offering investors a clear view of its current market value. Pfizer Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 19.68, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Pfizer Inc. also offers a dividend yield of 6.67%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Pfizer Inc. (PFE) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Pfizer Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Pfizer Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Pfizer Inc. is 15.5, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Pfizer Inc. (PFE) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Pfizer Inc. (PFE) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Pfizer Inc. (PFE) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Pfizer Inc.. To access the full SS Score, consider upgrading your subscription.
Pfizer Inc. is a significant player in the industry sector, with a market capitalization of $146.99B and a competitive P/E ratio of 19.68. Investors should compare these metrics with industry peers to gauge whether Pfizer Inc. is outperforming or underperforming within its sector.
Moderately bullish activity in Pfizer (PFE), with shares up 10c, or 0.41%, near $25.77. Options volume relatively light with 66k contracts traded and calls leading puts for a put/call ratio…
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a stra...
Pfizer (PFE) announced data from its Phase 2 study evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidat...
Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold higher antibody levels against a key strain...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investi...
Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed that President Donald Trump is set to announce…
10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and C...
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps an Underperform rating on the shares following what the firm calls…
Mixed options sentiment in Pfizer (PFE), with shares up 12c, or 0.48%, near $26.00. Options volume running well above average with 182k contracts traded and puts leading calls for a…
BofA analyst Tazeen Ahmad raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into…
Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi to include patients 12 years of age and older weighing at least…
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI® (marstacimab) t...
Pfizer ($PFE) delivered a solid Q1, reinforcing that the pharmaceutical giant’s core business remains relatively resilient even as COVID-related revenue continues fading into the background. However, ...
After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for the treatment of ER+/HER2-, ESR1-mutated a...
Arvinas (ARVN) and Pfizer (PFE) have entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the exclusive global development, manufacturing, and commercialization rights for Veppanu. V...
Rigel Pharmaceuticals (RIGL) announced that it has entered into an exclusive, global license agreement with Arvinas (ARVN) and Pfizer (PFE), subject to regulatory clearance, to develop, manufacture an...
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on ...
Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very c...
Pfizer CEO Albert Bourla says that company has reviewed its first AI-designed molecule. He says the company wants to be at the forefront of using artificial intellegence
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 18.77B | Analyst x5 | |
| 2027 | 17.54B | -6.58% | Analyst x7 |
| 2028 | 15.89B | -9.42% | Analyst x7 |
| 2029 | 15.43B | -2.89% | Analyst x6 |
| 2030 | 15.65B | 1.44% | Analyst x6 |
| 2031 | 15.46B | -1.20% | Est @-1.2% |
| 2032 | 15.45B | -0.04% | Est @0.0% |
| 2033 | 15.57B | 0.76% | Est @0.8% |
| 2034 | 15.77B | 1.25% | Est @1.2% |
| 2035 | 16.02B | 1.62% | Est @1.6% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 9.84B | 1.00 | 9.84B |
| 2025A | 9.08B | 1.00 | 9.08B |
| 2026E | 18.77B | 1.07 | 17.47B |
| 2027E | 17.54B | 1.15 | 15.19B |
| 2028E | 15.89B | 1.24 | 12.81B |
| 2029E | 15.43B | 1.33 | 11.57B |
| 2030E | 15.65B | 1.43 | 10.93B |
| 2031E | 15.46B | 1.54 | 10.05B |
| 2032E | 15.45B | 1.65 | 9.34B |
| 2033E | 15.57B | 1.78 | 8.76B |
| 2034E | 15.77B | 1.91 | 8.26B |
| 2035E | 16.02B | 2.05 | 7.81B |
| Terminal | 331.70B | 2.05 | 161.68B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.